MedTrace Logo

Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)

NCT07693257 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-07-09

No results posted yet for this study

Summary

This study examines how the psychedelic substance DMT affects the human brain when administered by the intravenous (IV) route. DMT is a naturally occurring chemical in the body that is thought to help improve mood when ingested in a continuously monitored medical setting. Previous research has shown that a single IV injection of DMT can be given safely, but its effects, which include changes in perception, emotions, and thinking, usually wear off within 15-20 minutes.

To better understand what happens when DMT's effects last longer, researchers have developed a method to give DMT slowly and continuously through an IV, which safely extends its effects for up to an hour or more. In this study, healthy volunteers who have prior experience using DMT will receive low and medium doses of DMT in this extended manner through an IV for 1 hour while undergoing a brain scanning technique known as functional magnetic resonance imaging (fMRI). These scans allow researchers to see changes in brain activity and blood flow in real time.

Participants will complete psychological assessments before and after receiving DMT, and additional brain scans without DMT will be used for comparison. The researchers will also use advanced computer techniques to help identify brain patterns linked to the visual experiences people report during DMT.

Overall, the goal of the study is to better understand how DMT affects the brain during an extended experience and to learn more about the biological processes behind its psychological effects.

Conditions

  • Healthy Participants Study

Interventions

DRUG

N,N-Dimethyltryptamine (15 mg)

Participants will receive one "low" dose (15 mg for 1 min + 1.5 mg/min for 59 min) of synthetic DMT (hemifumarate) via IV injection.

DRUG

N,N-Dimethyltryptamine (17.5 mg)

Participants will receive one "medium" dose (17.5 mg for 1 min + 1.75 mg/min for 59 min) of synthetic DMT (hemifumarate) via IV injection.

Sponsors & Collaborators

  • Jon Dean

    lead OTHER

Principal Investigators

  • Jon Dean, PhD · UCSD

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2028-09-01
Completion
2029-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07693257 on ClinicalTrials.gov